UpbeatA faster, triple-target cell therapy gives blood-cancer patients new hope
At Ohio State's cancer centre, Sumithira Vasu's team ran the first human trial of a CAR T-cell therapy — immune cells re-engineered to hunt cancer — that targets three proteins at once and returns the cells to patients in just six days. Published in Blood Cancer Discovery, the early trial showed positive outcomes with minimal side effects for people whose B-cell cancers had returned or stopped responding to treatment.
The upbeat factorfor patients who had run out of options, a stronger therapy arrived in six days, not weeks.
SDG 3 · Good health and well-being — Mechanism: tech innovation
Explore:
Healing